Mural Oncology PLC Sustainability Reports
Mural Oncology plc is a clinical-stage biotechnology company that leverages its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. The company's pipeline focus includes investigational therapies designed to deliver clinical benefits across a wide range of tumor types.
Sector: Manufacturing
Country: Ireland
Exchange: Nasdaq
FIGI: BBG01BCJBZC6
2 reports from 2023 to 2024
Company Profile
Mural Oncology plc is a clinical-stage biotechnology company that leverages its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. The company's pipeline focus includes investigational therapies designed to deliver clinical benefits across a wide range of tumor types.
Reports
2 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
